Cargando…

210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine

Introduction: We tested the total spike antibody (S-Ab), IgG/IgM S-Ab, and neutralizing antibody (N-Ab) responses of COVID-19-naïve subjects from before their first BNT162b2 vaccination up to 210 days after boosting. Methods: We studied 136 COVID-19-naïve subjects who received three doses of the Pfi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Chin Shern, Oh, May Lin Helen, Phua, Soon Kieng, Liang, Ya-Li, Aw, Tar Choon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607129/
https://www.ncbi.nlm.nih.gov/pubmed/36298568
http://dx.doi.org/10.3390/vaccines10101703
_version_ 1784818464842579968
author Lau, Chin Shern
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya-Li
Aw, Tar Choon
author_facet Lau, Chin Shern
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya-Li
Aw, Tar Choon
author_sort Lau, Chin Shern
collection PubMed
description Introduction: We tested the total spike antibody (S-Ab), IgG/IgM S-Ab, and neutralizing antibody (N-Ab) responses of COVID-19-naïve subjects from before their first BNT162b2 vaccination up to 210 days after boosting. Methods: We studied 136 COVID-19-naïve subjects who received three doses of the Pfizer mRNA vaccine (39 males, 97 females, mean age 43.8 ± 13.5 years) from January 2021 to May 2022. Serum was assessed for total S-Ab (Roche), IgG/M (Abbott), and N-Ab (Snibe). Results: Peak antibody levels were measured 20-30 days after each dose, with booster dosing eliciting significantly higher peak antibodies than the second dose: total S-Ab 2219 vs. 19,551 BAU/mL (difference 16,667 BAU/mL, p < 0.0001); IgG 2270 vs. 2932 BAU/mL (difference 660 BAU/mL, p = 0.04); and N-Ab 3.52 vs. 26.4 µg/mL (difference 21.4 µg/mL, p < 0.0001). Only IgM showed a lower peak post-booster antibody titer (COI 2.11 vs. 0.23, difference 1.63, 95% CI 1.05 to 2.38, p < 0.0001). By 180–210 days after the second or third vaccination, total S-Ab/IgG/N-Ab had decreased by 68.7/93.8/73.6% vs. 82.8/86.3/79.5%. The half-lives of IgG and N-Ab antibodies were longer after the third vaccination (IgG: 65 vs. 34 days, N-Ab: 99 vs. 78 days). Conclusion: Total S-Ab/IgG/N-Ab showed a greater increase post-booster, with IgG/N-Ab having a longer half-life.
format Online
Article
Text
id pubmed-9607129
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96071292022-10-28 210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine Lau, Chin Shern Oh, May Lin Helen Phua, Soon Kieng Liang, Ya-Li Aw, Tar Choon Vaccines (Basel) Article Introduction: We tested the total spike antibody (S-Ab), IgG/IgM S-Ab, and neutralizing antibody (N-Ab) responses of COVID-19-naïve subjects from before their first BNT162b2 vaccination up to 210 days after boosting. Methods: We studied 136 COVID-19-naïve subjects who received three doses of the Pfizer mRNA vaccine (39 males, 97 females, mean age 43.8 ± 13.5 years) from January 2021 to May 2022. Serum was assessed for total S-Ab (Roche), IgG/M (Abbott), and N-Ab (Snibe). Results: Peak antibody levels were measured 20-30 days after each dose, with booster dosing eliciting significantly higher peak antibodies than the second dose: total S-Ab 2219 vs. 19,551 BAU/mL (difference 16,667 BAU/mL, p < 0.0001); IgG 2270 vs. 2932 BAU/mL (difference 660 BAU/mL, p = 0.04); and N-Ab 3.52 vs. 26.4 µg/mL (difference 21.4 µg/mL, p < 0.0001). Only IgM showed a lower peak post-booster antibody titer (COI 2.11 vs. 0.23, difference 1.63, 95% CI 1.05 to 2.38, p < 0.0001). By 180–210 days after the second or third vaccination, total S-Ab/IgG/N-Ab had decreased by 68.7/93.8/73.6% vs. 82.8/86.3/79.5%. The half-lives of IgG and N-Ab antibodies were longer after the third vaccination (IgG: 65 vs. 34 days, N-Ab: 99 vs. 78 days). Conclusion: Total S-Ab/IgG/N-Ab showed a greater increase post-booster, with IgG/N-Ab having a longer half-life. MDPI 2022-10-12 /pmc/articles/PMC9607129/ /pubmed/36298568 http://dx.doi.org/10.3390/vaccines10101703 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lau, Chin Shern
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya-Li
Aw, Tar Choon
210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
title 210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
title_full 210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
title_fullStr 210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
title_full_unstemmed 210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
title_short 210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
title_sort 210-day kinetics of total, igg, and neutralizing spike antibodies across a course of 3 doses of bnt162b2 mrna vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607129/
https://www.ncbi.nlm.nih.gov/pubmed/36298568
http://dx.doi.org/10.3390/vaccines10101703
work_keys_str_mv AT lauchinshern 210daykineticsoftotaliggandneutralizingspikeantibodiesacrossacourseof3dosesofbnt162b2mrnavaccine
AT ohmaylinhelen 210daykineticsoftotaliggandneutralizingspikeantibodiesacrossacourseof3dosesofbnt162b2mrnavaccine
AT phuasoonkieng 210daykineticsoftotaliggandneutralizingspikeantibodiesacrossacourseof3dosesofbnt162b2mrnavaccine
AT liangyali 210daykineticsoftotaliggandneutralizingspikeantibodiesacrossacourseof3dosesofbnt162b2mrnavaccine
AT awtarchoon 210daykineticsoftotaliggandneutralizingspikeantibodiesacrossacourseof3dosesofbnt162b2mrnavaccine